AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19293292 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up care
Number of subjects: 44
Study 17286738 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients confident in managing their health
Number of subjects: 302
Study 17286738 — intervention group
Group type: COMPARATOR
Intervention: Patients less confident in managing their health
Number of subjects: 302
Study 15532347 — intervention group
Group type: EXPERIMENTAL
Intervention: BOOT STRAP intervention
Number of subjects: 801
Study 15532347 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 801
Study 15532347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 801
Study 15532347 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 801
Study 12401598 — intervention group
Group type: EXPERIMENTAL
Intervention: FLACC tool for pain assessment
Number of subjects: 79
Study 10448818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparing of the superior temporal gyrus
Number of subjects: 30
Study 10448818 — intervention group
Group type: COMPARATOR
Intervention: Resection of the superior temporal gyrus
Number of subjects: 30
Study 7482267 — intervention group
Group type: EXPERIMENTAL
Intervention: Early closure of colostomies
Number of subjects: 38
Study 7482267 — intervention group
Group type: COMPARATOR
Intervention: Late closure of colostomies
Number of subjects: 38
Study 2405737 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg atropine followed by 0.1 ml/kg 1% lidocaine with 1/200,000 epinephrine (0.5 micrograms/kg)
Number of subjects: 65
Study 2405737 — intervention group
Group type: COMPARATOR
Intervention: 0.1 ml/kg 1% lidocaine with 1/200,000 epinephrine (0.5 micrograms/kg) without atropine
Number of subjects: 65
Study 2405737 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg atropine followed by 0.1 ml/kg 1% lidocaine without epinephrine
Number of subjects: 65
Study 2405737 — intervention group
Group type: COMPARATOR
Intervention: 0.1 ml/kg 1% lidocaine without epinephrine without atropine
Number of subjects: 65
Study 6776586 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (moderate doses)
Number of subjects: 4
Study 6776586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 6830407 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 10
Study 6830407 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 10
Study 28990404 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic, feedback-intensive platform
Number of subjects: 664
Study 28990404 — intervention group
Group type: COMPARATOR
Intervention: Static intervention
Number of subjects: 664
Study 26102639 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients
Number of subjects: 0
Study 26102639 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24683578 — intervention group
Group type: COMPARATOR
Intervention: Collagen plug (control)
Number of subjects: 41
Study 24683578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralized freeze‐dried bone allograft (FDBA)/β‐tricalcium phosphate (β‐TCP)/collagen plug
Number of subjects: 41
Study 24683578 — intervention group
Group type: EXPERIMENTAL
Intervention: FDBA/β‐TCP/PRP/collagen plug
Number of subjects: 41
Study 24683578 — intervention group
Group type: EXPERIMENTAL
Intervention: FDBA/β‐TCP/rhPDGF‐BB/collagen plug
Number of subjects: 41
Study 22105872 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose IVLE (0.5 g kg(‐1) day(‐1) gradually increased to a maximum of 3.5 g kg(‐1) day(‐1))
Number of subjects: 42
Study 22105872 — intervention group
Group type: COMPARATOR
Intervention: Restricted-dose IVLE (1 g kg(‐1) day(‐1))
Number of subjects: 42
Study 22105872 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose IVLE
Number of subjects: 42
Study 22105872 — intervention group
Group type: COMPARATOR
Intervention: Restricted-dose IVLE
Number of subjects: 42
Study 20641098 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal caffeine intake with fast CYP1A2*1F oxidation status
Number of subjects: 768
Study 20641098 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant slow NAT2 acetylator status
Number of subjects: 768
Study 20641098 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers consuming caffeine with fast CYP1A2*1F and slow NAT2
Number of subjects: 768
Study 20641098 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal caffeine and infant CYP1A2*1F fast oxidizer status
Number of subjects: 768
Study 18540725 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinness expectancy manipulation
Number of subjects: 0
Study 18540725 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational intervention
Number of subjects: 0
Study 16032969 — intervention group
Group type: EXPERIMENTAL
Intervention: New divisible formulation of lamotrigine (100 mg)
Number of subjects: 48
Study 16032969 — intervention group
Group type: COMPARATOR
Intervention: Plain lamotrigine tablet
Number of subjects: 48
Study 16032969 — intervention group
Group type: COMPARATOR
Intervention: Dispersible/chewable lamotrigine tablet
Number of subjects: 48
Study 14593973 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (Ebixa‐‐Lundbeck Ltd)
Number of subjects: 0
Study 10476345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenocortical carcinomas with hypercorticoidism symptoms
Number of subjects: 15
Study 10476345 — intervention group
Group type: COMPARATOR
Intervention: Inactive adrenocortical carcinomas
Number of subjects: 15
Study 7571982 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (ascites and very low sodium excretion)
Number of subjects: 28
Study 7571982 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 28
Study 7571982 — intervention group
Group type: COMPARATOR
Intervention: Group A and B
Number of subjects: 28
Study 1720118 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage and physiotherapy
Number of subjects: 61
Study 1720118 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 61
Study 6820076 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition regimen with lipid emulsion
Number of subjects: 20
Study 6820076 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition regimen without lipid emulsion
Number of subjects: 20
Study 31151800 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mL of GC1109
Number of subjects: 104
Study 31151800 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL of GC1109
Number of subjects: 104
Study 31151800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mL of GC1109
Number of subjects: 104
Study 31151800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 0.5 mL)
Number of subjects: 104
Study 28977399 — intervention group
Group type: EXPERIMENTAL
Intervention: 100M allo-hMSCs
Number of subjects: 30
Study 28977399 — intervention group
Group type: EXPERIMENTAL
Intervention: 200M allo-hMSCs
Number of subjects: 30
Study 28977399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26242443 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous diclofenac (150 mg/day)
Number of subjects: 147
Study 26242443 — intervention group
Group type: COMPARATOR
Intervention: On-demand diclofenac
Number of subjects: 147
Study 26242443 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous diclofenac (150 mg/day) in C reactive protein positive or syndesmophytes patients
Number of subjects: 147
Study 26242443 — intervention group
Group type: COMPARATOR
Intervention: On-demand diclofenac in C reactive protein positive or syndesmophytes patients
Number of subjects: 147
Study 26242443 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous diclofenac (150 mg/day) in patients with syndesmophytes
Number of subjects: 147
Study 26242443 — intervention group
Group type: COMPARATOR
Intervention: On-demand diclofenac in patients with syndesmophytes
Number of subjects: 147
Study 25140770 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 239
Study 25140770 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium (LTRA)
Number of subjects: 239
Study 22342508 — intervention group
Group type: EXPERIMENTAL
Intervention: isobaric 2% lidocaine
Number of subjects: 84
Study 22342508 — intervention group
Group type: COMPARATOR
Intervention: isobaric 2% mepivacaine
Number of subjects: 84
Study 19709510 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm-tip catheter (Group 1)
Number of subjects: 131
Study 19709510 — intervention group
Group type: COMPARATOR
Intervention: Open irrigated-tip catheter (Group 2)
Number of subjects: 131
Study 19709510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 131
Study 17601189 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 12
Study 15240611 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH (1-34) 400 U daily for 12 months
Number of subjects: 51
Study 15240611 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy alone
Number of subjects: 51
Study 11795454 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (Copaxone)
Number of subjects: 156
Study 11795454 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta-1b (Betaseron)
Number of subjects: 156
Study 11795454 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta-1a (Avonex)
Number of subjects: 156
Study 11795454 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 156
Study 9572541 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate (LE), n=10, instilled one drop into each eye 8 times daily on Days 0 and 1 and four times daily on Days 2 through 42
Number of subjects: 14
Study 9572541 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=4, instilled one drop into each eye 8 times daily on Days 0 and 1 and four times daily on Days 2 through 42
Number of subjects: 14
Study 9572541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LE and placebo)
Number of subjects: 14
Study 9572541 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate (LE)
Number of subjects: 14
Study 7599515 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 0
Study 7599515 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 7599515 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 2450751 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (150 mg b.i.d.)
Number of subjects: 19
Study 2450751 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (150 mg t.i.d.)
Number of subjects: 19
Study 31681981 — intervention group
Group type: COMPARATOR
Intervention: Palliative Care Needs Rounds (monthly hour-long staff-only triage meetings)
Number of subjects: 1700
Study 31681981 — intervention group
Group type: COMPARATOR
Intervention: Palliative Care Needs Rounds
Number of subjects: 1700
Study 30085075 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B at 100 mg/kg twice daily for 10 days
Number of subjects: 36
Study 30085075 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B at 25 mg/kg twice daily for 10 days
Number of subjects: 36
Study 30085075 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 36
Study 28885428 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioral intervention during prenatal care visit (7‐ to 10‐minute in‐office intervention including a video and hygiene education using motivational interviewing, reminder calendar, and weekly text message reminders)
Number of subjects: 197
Study 28885428 — intervention group
Group type: COMPARATOR
Intervention: Standard care (a brochure)
Number of subjects: 197
Study 28885428 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioral intervention
Number of subjects: 197
Study 25332065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice
Number of subjects: 20
Study 25332065 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 20
Study 22915788 — intervention group
Group type: COMPARATOR
Intervention: Robotic ablation at 25 W for 30 s (R30)
Number of subjects: 20
Study 22915788 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic ablation at 25 W for 60 s (R60)
Number of subjects: 20
Study 22915788 — intervention group
Group type: COMPARATOR
Intervention: Manual ablation at 30 W for 60 s
Number of subjects: 20
Study 21335507 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (10 μg/dL increase)
Number of subjects: 3434
Study 21335507 — intervention group
Group type: COMPARATOR
Intervention: Lycopene (10 μg/dL increase) in placebo arm
Number of subjects: 3434
Study 19472387 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 24
Study 19472387 — intervention group
Group type: EXPERIMENTAL
Intervention: Kohonen and probabilistic neural network (KNN and PNN) analysis
Number of subjects: 24
Study 19472387 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration of contrast enhancement curves by PNN
Number of subjects: 24
Study 16954440 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 183
Study 16954440 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin + Tamoxifen
Number of subjects: 183
Study 16954440 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIX expression
Number of subjects: 183
Study 16954440 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of hormone sensitivity (bcl2, ER, PgR)
Number of subjects: 183
Study 15284501 — intervention group
Group type: EXPERIMENTAL
Intervention: Periradicular methylprednisolone (in combination with bupivacaine)
Number of subjects: 34
Study 15284501 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 34
Study 11773888 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg i.v. bolus on days 0 and 4)
Number of subjects: 138
Study 11773888 — intervention group
Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG) (15 mg/day i.v. for up to 14 days)
Number of subjects: 138
Study 11773888 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 138
Study 11773888 — intervention group
Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 138
Study 9460599 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuzea tincture
Number of subjects: 0
Study 9460599 — intervention group
Group type: EXPERIMENTAL
Intervention: Leveton
Number of subjects: 0
Study 9460599 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 8452344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension (20 mg/kg of body weight per day in two divided doses)
Number of subjects: 385
Study 8452344 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V suspension (50 mg/kg/day in three divided doses)
Number of subjects: 385
Study 3899250 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (n = 59)
Number of subjects: 178
Study 3899250 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy (n = 57)
Number of subjects: 178
Study 27888255 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct intervention effects on temptations for limiting high-fat foods
Number of subjects: 6516
Study 27888255 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct intervention effects on stage of change for limiting high-fat foods
Number of subjects: 6516
Study 29933868 — intervention group
Group type: EXPERIMENTAL
Intervention: Withania somnifera root extract
Number of subjects: 60
Study 29933868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25875939 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent with transcutaneous electrodes and aerobic exercise (30 minutes on cycloergometer) in IG1
Number of subjects: 42
Study 25875939 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent with transcutaneous electrodes and aerobic exercise (30 minutes on cycloergometer) in IG2
Number of subjects: 42
Study 25875939 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent with percutaneous electrodes and aerobic exercise (30 minutes on cycloergometer) in IG3
Number of subjects: 42
Study 25875939 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent applied simultaneously with aerobic exercise (30 minutes on cycloergometer) in IG4
Number of subjects: 42
Study 25875939 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG) with microcurrent device switched off
Number of subjects: 42
Study 23682155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction and exercise (DR + E) for 6 months
Number of subjects: 27
Study 23682155 — intervention group
Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 27
Study 21114380 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine up to 20 mg
Number of subjects: 29
Study 21114380 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) up to 25 mg
Number of subjects: 29
Study 21114380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 29
Study 20128377 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 8 weeks
Number of subjects: 149
Study 20128377 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (calcium antagonists, ACEI, diuretics, beta-receptor blocker for 8 weeks)
Number of subjects: 149
Study 17406887 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel group (FW)
Number of subjects: 24
Study 17406887 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ctrl)
Number of subjects: 24
Study 15183485 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) with daily RT in 3-Gy fractions, total dose of 21 Gy.
Number of subjects: 95
Study 15183485 — intervention group
Group type: COMPARATOR
Intervention: Sham radiotherapy (sham RT).
Number of subjects: 95
Study 11354587 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer of mental health services
Number of subjects: 0
Study 11354587 — intervention group
Group type: EXPERIMENTAL
Intervention: Person with severe mental illness
Number of subjects: 0
Study 11354587 — intervention group
Group type: EXPERIMENTAL
Intervention: Person with schizophrenia
Number of subjects: 0
Study 11354587 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic
Number of subjects: 0
Study 8039950 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic exercises for 1 month
Number of subjects: 10
Study 8039950 — intervention group
Group type: COMPARATOR
Intervention: Physical training (PT) exercises for 1 month
Number of subjects: 10
Study 3190131 — intervention group
Group type: EXPERIMENTAL
Intervention: Picolax given the day before irrigation
Number of subjects: 2
Study 3190131 — intervention group
Group type: COMPARATOR
Intervention: Enema regimen
Number of subjects: 2
Study 30829067 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy for insomnia (wCBT-I) coupled with general sleep education
Number of subjects: 35
Study 30829067 — intervention group
Group type: COMPARATOR
Intervention: General sleep education alone (wait-list control)
Number of subjects: 35
Study 31781700 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with provisional or customised healing abutment
Number of subjects: 40
Study 31781700 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin tissue phenotype
Number of subjects: 40
Study 31781700 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal implant position
Number of subjects: 40
Study 28054260 — intervention group
Group type: COMPARATOR
Intervention: High-speed handpiece (control)
Number of subjects: 40
Study 28054260 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (160 mJ; 3 Hz)
Number of subjects: 40
Study 28054260 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (260 mJ; 3 Hz)
Number of subjects: 40
Study 28054260 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (300 mJ; 3 Hz)
Number of subjects: 40
Study 26092495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium NO3(‐) (0.15 mmol NaNO3(‐) · kg(‐1))
Number of subjects: 17
Study 26092495 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 17
Study 22859712 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg once daily)
Number of subjects: 68
Study 22859712 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (320 mg once daily)
Number of subjects: 68
Study 22859712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 68
Study 21333871 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle-supported phakic intraocular lens (pIOL) implantation
Number of subjects: 360
Study 19890230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (n=124)
Number of subjects: 175
Study 19890230 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=41-66)
Number of subjects: 175
Study 17022982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation induction in a chronic low-dose step-up FSH regimen
Number of subjects: 85
Study 12620789 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial posting of foot orthotics
Number of subjects: 21
Study 12620789 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-molding of foot orthotics
Number of subjects: 21
Study 12620789 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medial posting and custom-molding of foot orthotics
Number of subjects: 21
Study 12620789 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 21
Study 10854561 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 82
Study 10854561 — intervention group
Group type: COMPARATOR
Intervention: 5-FU and LCV
Number of subjects: 82
Study 9272405 — intervention group
Group type: COMPARATOR
Intervention: Otilonium bromide 120 mg
Number of subjects: 16
Study 9272405 — intervention group
Group type: COMPARATOR
Intervention: Otilonium bromide (combined doses of 80, 160, and 240 mg)
Number of subjects: 16
Study 9272405 — intervention group
Group type: COMPARATOR
Intervention: Otilonium bromide (all doses)
Number of subjects: 16
Study 7712918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose cyclosporin A (CsA)
Number of subjects: 30